ACCORD HEALTHCARE LIMITED
Location
Founded
2004-04-13
Risk Signals
337 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Pharmaceutical Preparations, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about ACCORD HEALTHCARE LIMITED
Live alerts from global media, monitored by Business Radar
2024-09-30 (nature.com)
Enhancing severe hypoglycemia prediction in type 2 diabetes mellitus through multi-view co-training machine learning model for imbalanced dataset
Patients with type 2 diabetes mellitus (T2DM) who have severe hypoglycemia (SH) poses a considerable risk of long-term death, especially among the elderly, demanding urgent medical attention. Accurate prediction of SH remains challenging due to its multifaced nature, contributed from factors such as
Read more
2024-01-25 (pmlive.com)
ACCORD: new guideline to support consistent and complete reporting of consensus methods in biomedical research
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies.
Read more
2020-06-05 (pharmaceutical-journal.com)
Heparin and zilucoplan added to COVID-19 ACCORD trials platform
The National Institute for Health Research has confirmed that two more drugs will be included in a clinical trial scheme designed to speed up development of new medicines for patients hospitalised with COVID-19.
Read more
2014-01-14 (accord-healthcare.com)
Clinigen Group Extends Exclusive Agreement with Accord ...
News. All news. 2014-01-14. Clinigen Group Extends Exclusive Agreement with Accord Healthcare to Supply Anti-Cancer Drug Capecitabine into Clinical Trials in …
Read more